Pharming Group N.V., a specialty pharmaceutical company, develops and manufactures biopharmaceutical products in the United States, Europe, and internationally.
Exceptional growth potential with adequate balance sheet.
Share Price & News
How has Pharming Group's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: PHGN's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: PHGN exceeded the German Biotechs industry which returned 3.7% over the past year.
Return vs Market: PHGN exceeded the German Market which returned 6.1% over the past year.
Price Volatility Vs. Market
How volatile is Pharming Group's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Pharming Group undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: PHGN (€1.26) is trading above our estimate of fair value (€1.13)
Significantly Below Fair Value: PHGN is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: PHGN is good value based on its PE Ratio (21.4x) compared to the Biotechs industry average (37.5x).
PE vs Market: PHGN is poor value based on its PE Ratio (21.4x) compared to the German market (20.2x).
Price to Earnings Growth Ratio
PEG Ratio: PHGN is good value based on its PEG Ratio (0.6x)
Price to Book Ratio
PB vs Industry: PHGN is overvalued based on its PB Ratio (8.6x) compared to the DE Biotechs industry average (3.2x).
How is Pharming Group forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PHGN's forecast earnings growth (34.5% per year) is above the savings rate (-0.4%).
Earnings vs Market: PHGN's earnings (34.5% per year) are forecast to grow faster than the German market (13% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: PHGN's revenue (21.4% per year) is forecast to grow faster than the German market (5.1% per year).
High Growth Revenue: PHGN's revenue (21.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: PHGN's Return on Equity is forecast to be high in 3 years time (36.9%)
How has Pharming Group performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PHGN has a large one-off loss of €21.2M impacting its September 30 2019 financial results.
Growing Profit Margin: PHGN became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: PHGN has become profitable over the past 5 years, growing earnings by 6.8% per year.
Accelerating Growth: PHGN has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: PHGN has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).
Return on Equity
High ROE: PHGN's Return on Equity (38.9%) is considered high.
Return on Assets
Return on Capital Employed
How is Pharming Group's financial position?
Financial Position Analysis
Short Term Liabilities: PHGN's short term assets (€101.8M) exceed its short term liabilities (€90.1M).
Long Term Liabilities: PHGN's short term assets (€101.8M) exceed its long term liabilities (€40.2M).
Debt to Equity History and Analysis
Debt Level: PHGN's debt to equity ratio (59.8%) is considered high.
Reducing Debt: PHGN's debt to equity ratio has increased from 0% to 59.8% over the past 5 years.
Inventory Level: PHGN has a low level of unsold assets or inventory.
Debt Coverage by Assets: PHGN's debt is covered by short term assets (assets are 1.9x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: PHGN is profitable, therefore cash runway is not a concern.
Forecast Cash Runway: PHGN is profitable, therefore cash runway is not a concern.
What is Pharming Group's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate PHGN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate PHGN's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if PHGN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if PHGN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of PHGN's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Simon de Vries (60yo)
Dr. Sijmen De Vries, also known as Simon, M.D., MBA has been the Chief Executive Officer of Pharming Group NV since November 3, 2008 and has also been its Chairman and Member of the Management Board since ...
CEO Compensation Analysis
Compensation vs Market: Simon's total compensation ($USD1.48M) is about average for companies of similar size in the German market ($USD1.20M).
Compensation vs Earnings: Simon's compensation has been consistent with company performance over the past year.
|Chairman of Management Board & CEO||11.3yrs||€1.36m||1.1% €8.6m|
|Chief Medical Officer & Member of Management Board||13.2yrs||€839.00k||0.42% €3.3m|
|CFO & Member of Management Board||4.3yrs||€655.00k||0.041% €316.6k|
|Senior Vice President of Operations||0.3yrs||no data||no data|
|Chief Scientific Officer||5yrs||no data||no data|
|Senior Vice President of Organisational Development||6.1yrs||no data||no data|
|VP & Head of Non-US Commercial Operations||3.1yrs||no data||no data|
|Senior VP & GM of Pharming USA||3.1yrs||no data||no data|
|Head of Research & Development||0yrs||no data||no data|
|Head of Technical Operations||3.1yrs||no data||no data|
Experienced Management: PHGN's management team is considered experienced (4.3 years average tenure).
|Member of Board of Supervisory Directors||12.8yrs||€68.00k||0.038% €294.3k|
|Chairman of Board of Supervisory Directors||3.8yrs||€80.00k||0.067% €518.7k|
|Vice Chairman of the Board of Supervisory Directors||0yrs||€68.00k||0.070% €547.5k|
|Member of Board of Supervisory Directors||10.8yrs||€71.00k||0.029% €228.4k|
|Member of the Supervisor Board Director||1.1yrs||no data||no data|
Experienced Board: PHGN's board of directors are considered experienced (7.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: PHGN insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.1%.
Pharming Group N.V.'s company bio, employee growth, exchange listings and data sources
- Name: Pharming Group N.V.
- Ticker: PHGN
- Exchange: DB
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: €779.684m
- Shares outstanding: 631.32m
- Website: https://www.pharming.com
Number of Employees
- Pharming Group N.V.
- Darwinweg 24
- 2333 CR
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|PHGU.F||OTCPK (Pink Sheets LLC)||Yes||Ordinary Shares||US||USD||Oct 1998|
|PHARM||ENXTAM (Euronext Amsterdam)||Yes||Ordinary Shares||NL||EUR||Oct 1998|
|PHGN||DB (Deutsche Boerse AG)||Yes||Ordinary Shares||DE||EUR||Oct 1998|
|0QCO||LSE (London Stock Exchange)||Yes||Ordinary Shares||GB||EUR||Oct 1998|
|PHGN||BRSE (Berne Stock Exchange)||Yes||Ordinary Shares||CH||CHF||Oct 1998|
Pharming Group N.V., a specialty pharmaceutical company, develops and manufactures biopharmaceutical products in the United States, Europe, and internationally. The company’s lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema (HAE) in Europe, the United States, Israel, and South Korea. It also engages in the development of recombinant human factor VIII (rhFVIII), a natural human blood clotting factor for treating haemophilia A; and protein replacement treatments for enzyme-defi ciency disorders, such as pompe and fabry diseases, as well as products for contrast induced nephropathy. The company has a partnership with China Shanghai Institute of Pharmaceutical Industry for the development of new products; and development collaboration and license agreement with Novartis to develop and commercialize CDZ173, a small molecule phosphoinositide 3-kinase delta inhibitor to treat patients with activated phosphoinositide 3-kinase delta syndrome. Pharming Group N.V. is headquartered in Leiden, the Netherlands.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/25 21:03|
|End of Day Share Price||2020/02/25 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.